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The greater saphenous vein is the preferred con-
duit for infrainguinal arterial reconstruction, but for
various reasons, it may not be available for a com-
plete bypass graft. Frequently used alternatives, such
as nonautogenous graft materials, yield inferior graft
patency rates1-6 or are more prone to specific late
complications.7 As a consequence, considerable
attention has been directed toward all–autogenous
tissue reconstruction, a strategy that relies on the
better use of vein resources but also includes some
form of endarterectomy of the superficial femoral
artery (SFA).8,9
Initially termed intimectomy, eversion endar-
terectomy was developed before 1952 by Julian and
Dye10 and applied in several cases of long iliac and
femoral reconstructions. Other groups later refined
the technique by reducing the number of arteri-
otomies and removing a greater part of the medial
muscular fibers.11-14 Another refinement involved the
combination of eversion endarterectomy with a vein
segment to obtain an artery-vein graft.12 With this
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Objective: The purpose of this study was to determine the results of composite artery-
vein bypass grafting for infrainguinal arterial reconstruction.
Methods: This study was designed as a retrospective case series in two tertiary referral cen-
ters. Forty-eight of 51 patients underwent the procedure of interest for the treatment of
ischemic skin lesions (n = 42), rest pain (n = 3), disabling claudication (n = 1), and
infected prosthesis (n = 2). The intervention used was infrainguinal composite artery-
vein bypass grafting to popliteal (n = 18) and infrapopliteal (n = 30) arteries, with an
occluded segment of the superficial femoral artery prepared with eversion endarterecto-
my and an autogenous vein conduit harvested from greater saphenous veins (n = 43),
arm veins (n = 3), and lesser saphenous veins (n = 2). The main outcome measures, pri-
mary graft patency rates, foot salvage rates, and patient survival rates, were described by
means of the life-table method for a mean follow-up time of 15.5 months. 
Results: The cumulative loss during the follow-up period was 6% and 24% at 6 and 12
months, respectively. The primary graft patency rates, the foot salvage rates, and the
patient survival rates for patients with popliteal grafts were 60.0% ± 9.07%, 75.7% ±
9.18%, and 93.5% ± 6.03%, respectively, at 1 month; 53.7% ± 11.85%, 68.9% ± 12.47%,
and 85.0% ± 9.92% at 1 year; and 46.7% ± 18.19%, 68.9% ± 20.54%, and 53.1% ±
17.15% at 5 years. For infrapopliteal grafts, the corresponding estimates were 72.4% ±
7.06%, 72.9% ± 6.99%, and 92.7% ± 4.79% at 1 month; 55.6% ± 10.70%, 55.4% ±
10.07%, and 77.9% ± 9.02% at 1 year; and 33.6% ± 22.36%, 55.4% ± 30.20%, and 20.8%
± 9.89% at 5 years.
Conclusion: The composite artery-vein bypass graft is a useful autogenous alternative for
infrainguinal arterial reconstruction when a vein of the required quality is not available
or when the procedure needs to be confined to the affected limb. (J Vasc Surg
1999;29:413-21.)
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composite graft, we previously have reported on three
arterial reconstructions and the in situ replacement of
an infected femoropopliteal prosthetic graft.15 We
also have reported on the advantages of nonreversed
veins over reversed veins for single-length grafts and
composite artery-vein bypass grafts,16,17 and we have
adopted these techniques to maximize the use of
autogenous vein grafts.18 With the exception of a
recent report by Taylor et al19 on a series of 15 com-
posite artery-vein bypass grafts, we are unaware of
other publications on this subject. In this article, we
summarize our experience with composite artery-vein
bypass grafts for infrainguinal reconstruction.
METHODS
Patients. Fifty-one patients with angiographical-
ly proven long atherosclerotic occlusion of the SFA
and different degrees of involvement of popliteal and
tibial arteries underwent infrainguinal arterial recon-
struction with the composite artery-vein bypass graft.
The presence of heavily calcified or fibrotic arteries
precluded the development of a cleavage plane with-
in the arterial wall in three patients. These patients
underwent prosthetic femoropopliteal bypass graft-
ing and subsequently were excluded from the study.
Of the remaining 48 patients (38 men and 10
women; age range, 45 to 81 years; median age, 62
years), 13 (27%) had diabetes mellitus, 21 (44%) had
arterial hypertension, and 38 (79%) were smokers.
The main clinical problem consisted of nonhealing
ulcers or gangrene in 42 patients (87%), rest pain in
three patients (6%), infected femoropopliteal pros-
thesis in two patients (4%), and intermittent claudi-
cation in one patient (2%). Of the 42 patients with
skin lesions, ankle systolic blood pressure was 60 mm
Hg or more in seven patients and less than 60 mm
Hg in 16 patients, but no information could be
retrieved for the remaining 19 patients.
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Table I. Primary patency rates for all composite artery-vein bypass grafts
No. of 
censored grafts
No. of No. of failed Died with a Lost with a
Months grafts grafts patent graft End of Study patent graft IFR CPR (%) SE (%)
0 to 1 48 15 0 1 2 0.322 67.7 5.64
2 to 3 30 0 0 1 0 0 67.7 7.08
4 to 6 29 4 1 0 1 0.142 58 7.1
7 to 12 23 1 2 0 4 0.05 55.2 8.26
13 to 24 16 2 0 0 4 0.142 47.2 9.17
25 to 36 10 1 3 0 0 0.117 41.7 10.92
37 to 48 6 0 2 0 0 0 41.7 14.24
49 to 60 4 0 0 0 0 0 41.7 15.92
61 to 72 4 0 1 0 1 0 41.7 18.39
73 to 84 2 1 0 0 0 0.5 20.8 13.12
85 to 96 1 1 0 0 0 1 0 0
IFR, Interval failure rate; CPR, cumulative patency rate; SE, standard error.
Table II. Primary patency rates for 18 popliteal composite artery-vein bypass grafts
No. of 
censored grafts
No. of No. of failed Died with a Lost with a
Months grafts grafts patent graft End of Study patent graft IFR CPR (%) SE (%)
0 to 1 18 7 0 0 1 0.4 60 9.07
2 to 3 10 0 0 0 0 0 60 9.07
4 to 6 10 1 1 0 0 0.105 53.7 11.85
7 to 12 8 0 0 0 0 0 53.7 11.85
13 to 24 8 1 0 0 1 0.133 46.5 12.42
25 to 36 6 0 2 0 0 0 46.5 15.22
37 to 48 4 0 1 0 0 0 46.5 18.19
49 to 60 3 0 0 0 0 0 46.5 19.64
61 to 72 3 0 1 0 0 0 46.5 21.52
73 to 84 2 1 0 0 0 0.5 23.3 14.41
85 to 96 1 1 0 0 0 1 0 0
IFR, Interval failure rate; CPR, cumulative patency rate; SE, standard error.
Study design and patient assembling. This
investigation was a retrospective case series study of
patients who underwent treatment by nine different
surgeons from January 1976 to December 1997.
The following were indications for composite artery-
vein bypass grafts: insufficient length or small caliber
of veins in eight patients (17%); phlebitic scars in 11
patients (23%); the likelihood of technical enhance-
ment in eight patients (17%); absent veins in four
patients (8%); varicosities in three patients (6%); and
undetermined reasons in seven patients (15%). In
most cases, the decision for composite artery-vein
bypass grafting was subjective and was made when
unexpected problems were detected during surgery.
In such circumstances, the contralateral greater
saphenous vein was not harvested because of the
presence of bilateral arterial occlusions, because of
the convenience of confining the surgical procedure
to the affected limb, or because this vessel simply
was unavailable or unsuitable for use.
Surgical technique. Eversion endarterectomy
for the construction of composite artery-vein bypass
grafts has been well described elsewhere.15 Because
the amount of available vein determined the require-
ments for arterial tissue, the entire SFA was some-
times mobilized, whereas in other occasions a seg-
ment as short as 5 cm was sufficient. When the
required length was obtained, the SFA was distally
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Table III. Primary patency rates for 30 infrapopliteal composite artery-vein bypass grafts
No. of 
censored grafts
No. of No. of failed Died with a Lost with a
Months grafts grafts patent graft End of Study patent graft IFR CPR (%) SE (%)
0 to 1 30 8 0 1 1 0.275 72.4 7.06
2 to 3 20 0 0 1 0 0 72.4 8.61
4 to 6 19 3 0 0 1 0.162 60.7 8.84
7 to 12 15 1 2 0 4 0.083 55.6 10.7
13 to 24 8 1 0 0 3 0.153 47 13.43
25 to 36 4 1 1 0 0 0.285 33.6 14.64
37 to 48 2 0 1 0 0 0 33.6 22.36
49 to 60 1 0 0 0 0 0 33.6 27.38
61 to 72 1 0 0 0 1 0 33.6 38.73
IFR, Interval failure rate; CPR, cumulative patency rate; SE, standard error.
Fig 1. Cumulative life-table analysis patency rates for all 48 grafts. Standard error is represented with
vertical bars.
transected and raised from its natural bed. Heparin
was administered, and clamps were applied to the
femoral bifurcation. A longitudinal arteriotomy was
made in the common femoral artery and sometimes
extended into the SFA. Local endarterectomy was
accomplished, and a cleavage plane was developed
for eversion of the SFA. The atheromatous core then
was gently pulled through the arteriotomy, and the
eversion procedure advanced along the SFA until its
distal end was everted and the diseased intima
detached from the arterial wall. When as much cir-
cular muscle as possible had been removed and a
smooth inner surface was obtained, the endarterec-
tomized SFA was returned to its normal position
and its small branches were tied. The arteriotomy
then was closed directly or with an autogenous
patch.
The preceding standard technique was used in
32 reconstructions (standard grafts), but several
modifications were adopted in the other 16 (non-
standard grafts). The most common modification
was the translocation of the endarterectomized SFA
to a more proximal level to enhance the eversion
procedure (two grafts), to avoid a hostile common
femoral artery in reoperations (two grafts), or to
reach a better preserved vessel in the presence of an
infected prosthesis (one graft). Other modifications
included the relocation of the SFA to the deep
femoral artery (three grafts), the harvesting of the
distal half of the SFA (two grafts), the construction
of an end-to-end anastomosis with the common
femoral artery (two grafts), the use of an SFA that
had undergone endarterectomy a few months earli-
er (one graft), the lowering of the femoral bifurca-
tion (one graft), the extension of endarterectomy to
the iliac artery (one graft), and the conversion to
open endarterectomy (one graft). Endarterectomy
also included the orifice of the deep femoral artery
in the last three of the above-mentioned nonstan-
dard grafts and in all standard grafts.
The vein segments consisted of 41 greater saphe-
nous veins, two lesser saphenous veins, two arm
veins, two composite spliced saphenous and arm
veins, and one composite spliced saphenous vein. Of
the 41 single-length greater saphenous veins, 28
were reversed before implantation and 13 were used
in the nonreversed state.17 The recipient artery was
the above-knee popliteal artery in nine patients
(19%), the below-knee popliteal artery in nine
patients (19%), the anterior tibial artery in nine
patients (19%), the posterior tibial artery in 12
patients (25%), the peroneal artery in eight patients
(17%), and the dorsal pedal artery in one patient
(2%). After the completion of the distal vein-to-
artery anastomosis, the endarterectomized artery
was sewn end-to-end to the vein, which thus con-
cluded the reconstruction. Completion arteriograms
were not performed, nor was a postoperative policy
of anticoagulation therapy or antiplatelet therapy
adopted.
Assessment of results. The patients were
instructed to return to the outpatient clinic in
intervals of 3 months during the first postoperative
year and 6 months thereafter, but the cumulative
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Table IV. Influence of selected variables on primary graft patency rates (%)
Length of follow-up period
No. of grafts 1 month 1 year 2 years 3 years 4 years 5 years
Popliteal grafts
Nonstandard technique 11 42.9 42.9 42.9 42.9 42.9 42.9
Standard technique 7 85.7 70.1 52.6 52.6 52.6 52.6
Reoperation 7 57.1 57.1 42.9 42.9 42.9 42.9
First operation 11 61.9 50.6 50.6 50.6 50.6 50.6
Small caliber or postphlebitic vein 6 50 50 50 50 50 50
Other vein 12 65.2 55.2 42.9 42.9 42.9
Infrapopliteal grafts
Nonstandard technique 12 65.2 38.1 38.1 38.1 38.1 38.1
Standard technique 18 77.1 65.3 52.2 31.3 31.3 31.3
Reoperation 6 81.8 19.5
First operation 24 70.2 60.8 51.5 36.8 36.8 36.8
Small caliber or postphlebitic vein 12 66.7 50.0 50.0 25.0 25.0 25.0
Other vein 18 76.5 59.3 42.3 42.3 42.3
loss during the follow-up period was 6% and 24% at
6 and 12 months, respectively. Graft failure, major
amputation, and death—the outcomes of inter-
est—were assessed according to the recommenda-
tions by Rutherford et al.20 Graft patency rates
were determined with clinical evaluation in most
follow-up visits for 33 patients who had early graft
success. However, at least one postoperative
arteriogram was obtained for the three patients
with subcutaneous grafts and the six other patients
with grafts in a deeper plane. Nine other subcuta-
neously placed grafts were assessed confidently
with palpation. Of the remaining 15 patients, six
had documented Doppler scan measurements,
which left nine patients in whom palpation of arte-
rial pulses was the only method used to assess
patency. In the present study, primary and sec-
ondary graft failure did not differ for any patient.
The actuarial life-table analysis method was used to
describe graft patency rates (Tables I to III), foot
salvage rates, and patient survival rates.20 The
effect of a nonstandard surgical technique, reoper-
ations, and small caliber/postphlebitic veins on
graft patency rates also was investigated (Table IV).
Because the structural stability of initially patent
eversion endarterectomy segments has been chal-
lenged,19 we estimated this stability for composite
artery-vein bypass grafts during the first year of fol-
low-up with the ratio between the 12-month and
1-month graft patency rates shown in Tables I to
III and termed this ad hoc measure the 1-year graft
stability ratio.
RESULTS
Fifteen composite artery-vein bypass grafts failed
within 30 days, and 10 others failed later. The early
failures included the following: one rupture of a graft
performed for the in situ replacement of an infected
prosthetic bypass graft; three ruptures in four grafts
involved in postoperative wound infection; and 11
occlusions of uninfected grafts. The site of rupture
was the artery-vein anastomosis in three patients, but
it was not clearly identified in the remaining patient.
Four of the 11 patients with early occlusion of an
uninfected graft underwent reoperation. The
attempts at thrombectomy failed in three of those
patients, whereas a prosthetic femoropopliteal bypass
grafting was successfully performed in the other
patient. Another patient underwent a successful pro-
fundaplasty after late graft occlusion. The cause of
the late graft failure was determined for only two of
10 patients. One of those patients had a myocardial
infarction that lead to heart failure, graft occlusion,
and death. The other patient had an unsuspected
inflow stenosis. The mean follow-up time was 15.5
months for all 48 composite artery-vein bypass grafts
and 22.1 months for the 33 grafts that did not fail
within 1 month.
The graft patency rates at 1 month, 1 year, and 5
years were 67.7%, 55.1%, and 41.7%, respectively
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Fig 2. Cumulative life-table analysis patency rates for 18 popliteal grafts. Standard error is represent-
ed with vertical bars.
(Table I, Fig 1). The corresponding figures were
60.0%, 53.7%, and 46.5% for popliteal grafts (Table
II, Fig 2) and 72.4%, 55.6%, and 33.6% for
infrapopliteal grafts (Table III, Fig 3). If we consid-
er the 39 below-knee composite artery-vein bypass
grafts (nine popliteal and 30 infrapopliteal) to be a
distinct subgroup, then the corresponding estimates
would be 65.8%, 50.0%, and 32.8%. The 1-year graft
stability ratio was 81.4% for all grafts, 89.5% for
popliteal grafts, 76.8% for infrapopliteal grafts, and
76.0% for below-knee grafts. If the other three
attempted, but not completed, popliteal composite
artery-vein bypass grafts were included in an inten-
tion-to-treat perspective and were properly consid-
ered as graft failures, then the patency rate estimates
in Table I would decrease by 1.9%. An adverse effect
on graft patency was found for nonstandard surgical
technique, reoperation, and small caliber or post-
phlebitic veins (Table IV).
There were 12 early and five late major amputa-
tions. The cumulative foot salvage rates for all 48
limbs are shown in Table V. These estimates were
slightly better for popliteal artery than infrapopliteal
artery grafts: 75.7% versus 72.9% at 1 month and
68.9% versus 55.4% at 1 year and 5 years, respec-
tively. Four patients died within 30 days, one of
these after the rupture of the composite artery-vein
bypass graft performed for the in situ replacement of
an infected prosthesis. Thirteen other patients died
later. The cumulative patient survival rates are
shown in Table VI. As for foot salvage rates, the esti-
mates of patient survival rates were higher for
patients with popliteal grafts as compared with those
with infrapopliteal grafts (93.5% versus 92.7% at 1
month, 85.0% versus 77.9% at 1 year, and 53.1% ver-
sus 20.8% at 5 years).
DISCUSSION
As a consequence of intraoperative decision mak-
ing, this study sample refers to the population of
patients who have a chronically occluded superficial
femoral artery and need an infrainguinal bypass graft
but do not have good quality saphenous veins.
Surgeons usually resort to composite artery-vein
bypass grafts as a variant of autogenous vein grafts
when vein problems are found during surgery. Such
problems include structural defects that may be
identified with preoperative duplex ultrasound scan
evaluation, but this technology was not available at
the time that the first 42 grafts were performed, nor
was it used in the other six cases. The extent to
which duplex scanning will affect the use of com-
posite artery-vein bypass grafts may be limited by a
sensitivity of 62% in the diagnosis of small or dis-
eased veins and a prevalence rate of 12% for these
conditions.21 Whatever the proper role of composite
artery-vein bypass grafts may be, their ability 
to reduce the use of a prosthesis and to confine 
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Fig 3. Cumulative life-table analysis patency rates for 30 crural grafts. Standard error is represented
with vertical bars.
the procedure to the affected limb is obvious.
Unfortunately, their presumed greater resistance to
infection15 was not supported by our findings
because the early rupture of three infected grafts was
observed.
Visual control in the removal of medial circular
muscular fibers (a distinct advantage of eversion
endarterectomy over semiclosed endarterectomy) is
achieved at the price of greater damage to the
remaining adventitial layer,19 although the clinical
importance of such damage has not been objective-
ly documented. Contrary to the argument for
increased damage, Taylor et al19 have found similar
rates of graft stenosis and differences of less than
10% in patency rates when comparing artery-vein
grafts and saphenous grafts. Although inferior to the
results reported for other series of autogenous vein
grafts,22-24 our overall results with artery-vein grafts
were similar to those obtained in our institution for
a historical series of 168 infrainguinal reconstruc-
tions, 148 of which were autogenous grafts.18 In
addition, standard grafts, which more properly
reflect the potential of composite artery-vein bypass
grafts, performed moderately better than nonstan-
dard grafts (Table IV). However, a limitation involv-
ing no fewer than 18 of our artery-vein grafts (37%)
is that the vein segments, when harvested from small
caliber or postphlebitic veins, are associated with
lower graft patency rates.21
Because the superiority of the greater saphenous
vein graft for infrapopliteal reconstruction is beyond
any doubt, other alternatives should always be com-
pared with this graft. When all 29 crural composite
artery-vein bypass grafts are compared with our his-
torical series of 55 in situ crural saphenous vein
bypass grafts,16 the differences in patency rate esti-
mates (<5% at most time intervals) are compatible
with clinical equivalence. Furthermore, the 1-year
stability ratios for initially patent crural grafts (76.8%
for composite artery-vein bypass grafts and 78.4%
for in situ grafts) do not support the hypothesis of a
lower durability for eversion endarterectomy seg-
ments that is accepted by others.19
Because of our preference for autogenous grafts,
we only rarely use protheses or allografts as bypass
grafts to below-knee arteries. The 2-year primary
patency rate of 43.7% for our 39 below-knee com-
posite artery-vein bypass grafts was equivalent to the
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Table V. Limb salvage rates for all 48 patients with composite artery-vein bypass grafts
No. of No. of No. of
Months limbs amputated limbs censored limbs IAR CSR (%) SE (%)
0 to 1 48 12 4 0.26 73.9 5.57
2 to 3 32 1 2 0.032 71.5 6.85
4 to 6 29 2 2 0.071 66.4 7.27
7 to 12 25 2 5 0.089 60.5 8.02
13 to 24 18 0 7 0 60.5 9.99
25 to 36 11 0 5 0 60.5 13.04
37 to 48 6 0 2 0 60.5 17
49 to 60 4 0 0 0 60.5 19.01
61 to 72 4 0 2 0 60.5 21.95
193 to 204 2 0 2 0 60.5 38.03
IAR, Interval amputation rate; CSR, cumulative salvage rate; SE, standard error.
Table VI. Survival rates for all 48 patients with composite artery-vein bypass grafts
No. of patients No. of patients No. of censored 
Months at start who died patients IDR CSR (%) SE (%)
0 to 1 48 3 10 0.07 93 3.75
2 to 3 35 1 2 0.029 90.3 4.82
4 to 6 32 1 2 0.032 87.4 5.58
7 to 12 29 2 5 0.075 80.8 6.88
13 to 24 22 1 6 0.053 76.5 8.5
25 to 36 15 5 1 0.345 50.1 9.3
37 to 48 9 2 2 0.25 37.6 10.5
49 to 60 5 0 0 0 37.6 13.28
61 to 72 5 1 2 0.25 28.2 11.95
193 to 204 2 0 2 0 28.2 23.9
IDR, Interval death rate; CSR, cumulative survival rate; SE, standard error.
rate achieved in a multicenter study with 111 poly-
tetrafluoroethylene (PTFE) grafts.25 This was in
spite of a smaller proportion of crural grafts (1:6.7)
in the latter study. Crural allograft vein bypass grafts,
which have yielded 1-year patency rates of less than
40% and negligible 5-year patency rates,3-5 are clear-
ly inferior to crural composite artery-vein bypass
grafts. Our results with the latter were somewhat
better than those of Morris et al26 for a huge series
of 201 PTFE grafts, most of which included a vein
collar. Primary patency rates for infrapopliteal PTFE
grafts after 1 year and 5 years have been reported as
74% and 54% when a vein patch is used,27 and as
71% and 28% when no such patch is inserted.28 Our
three selected subgroups of crural composite artery-
vein bypass grafts (18 standard grafts, 24 first grafts,
and 17 grafts performed with better veins) yielded
results that were similar to those achieved for non-
patched PTFE grafts28 but inferior to those obtained
with patched PTFE grafts (Table IV).27 A summary
of the results of 13 other studies on PTFE grafts as
quoted in the above two reports revealed graft
patency rates that were lower than our 1-year esti-
mate in 11 of 13 studies and lower than our 5-year
estimate in 9 of 11 studies.27,28 Our results with
infrapopliteal composite artery-vein bypass grafts
thus were superior to those results achieved in most
selected series of PTFE grafts.
Because the results of the current study possibly
were adversely affected by the 20-year inclusion
period, a learning curve, and a large number of sur-
geons performing the procedures, they may not
reflect the true potential of composite artery-vein
bypass grafts for infrainguinal reconstruction.
However, they were satisfactory enough to support
the belief that this graft is a useful autogenous alter-
native when a vein of the required quality is not
available or when the procedure needs to be con-
fined to the affected limb.
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